Doherty Institute

Sharing our work showing that Helicobacter pylori induces the production of interleukin-37 by epithelial cells to promote broad immunosuppression, enhance colonisation and promote pathogenesis. Fantastic collaboration with @NoldLab and team @TheDohertyInst #d1e1215" target="_blank" rel="nofollow noopener">tandfonline.com/doi/10.1080/19…

🔬 50 years of electron microscopy (EM) at VIDRL, from Australia’s first HIV ultrastructural images in the 1980s to the first local images of SARS‑CoV‑2. EM is a vital tool for detecting and characterising pathogens during outbreaks. Find out more 🔗 bit.ly/4sLZOoK

Interested in helping research looking at immune responses to vaccines against mosquito-borne diseases? If you’re 18 -60 years with no serious immune problems, you may be eligible for our study in Melbourne. 🔗 For more info visit bit.ly/47JVRIl

Big few weeks with #PENFAST making it to Hollywood 🎥… but this might be even better 👇 The @ProspectorTrial #PROSPECTOR1 Trial led by @Austin_Health and @TheDohertyInst is now published in @NEJMEvidence 🔥 ➡️ evidence.nejm.org/doi/full/10.10… ✅ First double-blind, placebo-controlled trial in #drugallergy ✅ Pilot feasibility RCT (n=120) ✅ Single-dose vs 5-day amoxicillin challenge in delayed/unknown #penicillinallergy It was feasible and safe — and showed a 6.7% increase in immune-mediated reactions in the (multi-dose) arm. Nice Editorial: ➡️ evidence.nejm.org/doi/full/10.10… We’re getting closer to answering the question… Is one dose ever enough? 👀 #PROSPECTOR2 now recruiting (doi: 10.1136/bmjopen-2024-094712)

Interested in helping research looking at immune responses to vaccines against mosquito-borne diseases? If you’re 18 -60 years with no serious immune problems, you may be eligible for our study in Melbourne. 🔗 For more info visit bit.ly/47JVRIl

A new collaborative study has developed HIV‑seq, a tool that profiles rare HIV‑infected cells in people living with HIV. The breakthrough offers new insight into how these cells behave and could help guide future treatment strategies. bit.ly/3OQVhmA

A world-first portable point-of-care test detects syphilis, herpes, chlamydia & gonorrhoea simultaneously in under an hour — helping reduce misdiagnosis and cut transmission. doherty.edu.au/articles/new-r…

Interested in helping research looking at immune responses to vaccines against mosquito-borne diseases? If you’re 18 -60 years with no serious immune problems, you may be eligible for our study in Melbourne. 🔗 For more info visit bit.ly/47JVRIl

Could one vaccine protect against multiple deadly bacterial infections? Researchers have developed a promising preclinical vaccine targeting both golden staph & pneumococcal disease, as reported in Nature Microbiology. bit.ly/4aBEiM8

New research uncovers gamma‑delta T cells send a crucial signal through production of cytokine interleukin‑4, that helps the body fight parasitic infection, malaria. These findings offer new insights for boosting future vaccines and treatments. bit.ly/4anRANm

Interested in helping research looking at immune responses to vaccines against mosquito-borne diseases? If you’re 18 years or older with no serious immune problems, you may be eligible for our study in Melbourne. 🔗 For more info visit bit.ly/47JVRIl

A new way to tackle antibiotic‑resistant infections. Researchers have engineered antibodies that target pseudaminic acid — a sugar found only on bacterial cells — helping the immune system precisely identify and destroy drug‑resistant bacteria. bit.ly/45PSbVx

With Nipah making headlines again, it’s important to ask: what are the facts? Nipah virus is not new, cases remain limited, and outbreaks over the past two decades have been closely managed. In public health, following the facts matters. 🔗 bit.ly/4qXDU1l

Ever wondered why gamma delta T cells are required for immunity to liver-stage malaria? Spoiler - they make IL-4! @TheDohertyInst @NatImmunol nature.com/articles/s4159…

Exhausted T cells and TRM cells may look alike, but a new study finds key differences across cancers that could impact immunotherapy. One recognises tumour “tags,” the other reflects past infections, like flu, and must be deliberately engaged. bit.ly/3M365Ni

💊Drug Hypesensitivity Symposium 2026 - #DHS2026 Registrations are now open for our amazing 3-day #drugallergy & #antibioticallergy program in Melbourne 23-25th October 2026. Stellar international🌏speaker lineup. @eaaci @TheDohertyInst @nace_aus @CAAR_Aus ➡️dhs2026.org

A little behind on the HPAI tweets owing to being in Antarctica. A real privilege to be able to visit this incredible part of the world, but sadly, to better understand the ecology of this devastating virus.

What’s the latest on COVID-19 antivirals? Community Advisory Board member Mohamed Mohideen chats with infectious diseases physician A/Prof Katherine Gibney, in our new video series, Questions from the Community. 📹 Watch here: bit.ly/4syjmh0

2025 was a surprising year for flu, with cases extending beyond winter, a new subclade-K variant emerging and a boost in cases at the start of Summer. What does this activity tell us about the year ahead? 🔗 doherty.edu.au/news-events/ne…

Check out the program for #DHS2026 @EAACI_HQ @TheDohertyInst 😳😍All things #drugallergy and #antibioticallergy. See you in Melbourne!! ☕️🦘☀️🇦🇺 🔜 dhs2026.org